よりよい白血病治療のために
HOME >> JALSG業績 >> JALSG論文集の掲載

JALSG論文集の掲載

JALSG論文集

(JALSG論文をご発表の際は、必ず事務局までご報告下さい。)

【論文タイトル /// 全著者名 /// 掲載誌】           (2015/12/22更新)

128. Unrelated bone marrow transplantation or immediate umbilical cord blood 
   transplantation for patients with acute myeloid leukemia in first complete
    remission./// Yanada M, Kanda J, Ohtake S, Fukuda T, Sakamaki H, Miyamura K,
    Miyawaki S, Uchida N, Maeda T, Nagamura-Inoue T, Asou N, Morishima Y, Atsuta Y,
    Miyazaki Y, Kimura F, Kobayashi Y, Takami A, Naoe T, Kanda Y./// 
   Eur J Haematol. 2015 Dec 18. [Epub ahead of print]

127. Tamibarotene As Maintenance Therapy for Acute Promyelocytic Leukemia:
       Results From a Randomized Controlled Trial. /// Shinagawa K, Yanada M,
       Sakura T, Ueda Y, Sawa M, Miyatake J, Dobashi N, Kojima M, Hatta Y,
       Emi N, Tamaki S, Gomyo H, Yamazaki E, Fujimaki K, Asou N, Matsuo K,
       Ohtake S, Miyazaki Y, Ohnishi K, Kobayashi Y, Naoe T. /// J Clin Oncol.
        10;33(2):228. 2015    

126. Markedly improved outcomes and acceptable toxicity in adolescents and
       young adults with acute lymphoblastic leukemia following treatment with
       a pediatric protocol: a phase II study by the Japan Adult Leukemia Study
       Group /// F Hayakawa, T Sakura, T Yujiri, E Kondo, K Fujimaki, O Sasaki,
       J Miyatake, H Handa, Y Ueda, Y Aoyama, S Takada, Y Tanaka, N Usui,
       S Miyawaki, S Suenobu, K Horibe, H Kiyoi, K Ohnishi, Y Miyazaki. S Ohtake,
       Y Kobayashi, K Matsuo and T Naoe for the Japan Adult Leukemia Study
       Group(JALSG) /// Blood Cancer Journal(2014) 4, e252

125. Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic
       trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.
       /// Mannis GN, Logan AC, Leavitt AD, Yanada M, Hwang J, Olin RL, Damon LE,
       Andreadis C, Ai WZ, Gaensler KM, Greene CC, Gupta NK, Kaplan LD,
       Mahindra A, Miyazaki Y, Naoe T, Ohtake S, Sayre PH, Smith CC, Venstrom JM,
       Wolf JL, Caballero L, Emi N, Martin TG./// Bone Marrow Transplant. 2014 Sep 22.
       [Epub ahead of print]

124. Comprehensive analysis of genetic alterations and their prognostic impacts
       in adult acute myeloid leukemia patients. /// Kihara R, Nagata Y, Kiyoi H,
       Kato T, Yamamoto E, Suzuki K, Chen F, Asou N, Ohtake S, Miyawaki S,
       Miyazaki Y, Sakura T, Ozawa Y, Usui N, Kanamori H, Kiguchi T, Imai K,
       Uike N, Kimura F, Kitamura K, Nakaseko C, Onizuka M, Takeshita A, Ishida F,
       Suzushima H, Kato Y, Miwa H, Shiraishi Y, Chiba K, Tanaka H, Miyano S,
       Ogawa S, Naoe T./// Leukemia. 28(8):1586-95. 2014

123.Normal karyotype acute myeloid leukemia with the CD7+ CD15+
       CD34+ HLA-DR + immunophenotype is a clinically distinct entity
       with a favorable outcome./// Iriyama N, Asou N, Miyazaki Y, Yamaguchi S,
       Sato S, Sakura T, Maeda T, Handa H, Takahashi M, Ohtake S, Hatta Y,
       Sakamaki H, Honda S, Taki T, Taniwaki M, Miyawaki S, Ohnishi K,
       Kobayashi Y, Naoe T./// Ann Hematol. 93(6): 957-63. 2014

122. CD56 expression is an independent prognostic factor for relapse in acute
       myeloid leukemia with t(8;21)./// Iriyama N, Hatta Y, Takeuchi J, Ogawa Y,
       Ohtake S, Sakura T, Mitani K, Ishida F, Takahashi M, Maeda T, Izumi T,
       Sakamaki H, Miyawaki S, Honda S, Miyazaki Y, Taki T, Taniwaki M, Naoe T.
       /// Leuk Res. 2013 Sep;37(9):1021-6.

121.Role of hematopoietic stem cell transplantation for relapsed
       acute promyelocytic leukemia: a retrospective analysis of  JALSG-
       APL97. /// Fujita H, Asou N, Iwanaga M, Hyo R, Nomura S, Kiyoi H,
       Okada M, Inaguma Y, Matsuda M, Yamauchi T, Ohtake S, Izumi T,
       Nakaseko C, Ishigatsubo Y, Shinagawa K, Takeshita A, Miyazaki Y,
       Ohnishi K, Miyawaki S, Naoe T; Japan Adult Leukemia Study Group.
       /// Cancer Sci. 2013 Oct;104(10):1339-45.

120.The demarcation between younger and older acute myeloid
    leukemia patients: a pooled analysis of 3 prospective studies.
    /// Yanada M, Ohtake S, Miyawaki S, Sakamaki H, Sakura T, Maeda
    T, Miyamura K,Asou N, Oh I, Miyatake J, Kanbayashi H, Takeuchi
    J, Takahashi M, Dobashi N, Kiyoi K, Miyazaki Y, Emi N,Kobayashi Y,
    Ohno R, Naoe T/// Cancer. 119(18): 3326-33. 2013

119.Phase 2 study of arsenic trioxide followed by autologous
    hematopoietic cell transplantation for relapsed acute
    promyelocytic leukemia./// Yanada M, Tsuzuki M, Fujita H, Fujimaki
    K, Fujisawa S,Sunami K,Taniwaki M, Ohwada A, Tsuboi K, Maeda
    A, Takeshita A, Ohtake S, Miyazaki Y, AtsutaY, Kobayashi Y, Naoe
    T, Emi N/// Blood. 121:3095-3102.2013

118.Clinical studies of acute myeloid leukemia in the Japan Adult Leukemia
       Study Group./// S Miyawaki /// Int J Hematol.  Aug;96(2):171-7. 2012

117.Phase 1 trial of gemtuzumab ozogamicin in combination with
    enocitabine and daunorubicin for elderly patients with relapsed or
    refractory acute myeloid leukemia: Japan Adult Leukemia Study
    Group (JALSG)-GML208 study./// Y Ito, A Wakita, S Takada, M
    Mihara, M Gotoh, K Ohyashiki, S Ohtake, S Miyawaki, K Ohnishi, O
    Naoe/// Int J Hematol 96(4):485-91.2012

 116.Long-term outcome and prognostic factors of elderly patients with
     acute promyelocytic leukemia./// T Ono, A Takeshita, U Kishimoto,
     H Kiyoi, M Okada, T Ymauchi, M Tsuzuki, K Horikawa, M Matuda, K
     Shinagawa, F Monma, S Ohtake, C Nakaseko, M Takahashi, U
     Kimura,M Iwanaga, N Asou, adn O Naoe for the Japan Adult
     Leukemia Study Group/// Cancer Sci 103(11):1974-8. 2012

115.Randomized comparison of fixed-schedule versus response-
       oriented individualized induction therapy and use of ubenimex
       during and after consolidation therapy for eldery patients with
   acute myeloid leukemia:the JALSG GML200 Study/// A wakita, H
   Ohteke, S Takada, F Yagasaki, H Komatsu, Y Miyazaki, et al./// Int
   J Hematol 96(4):485-91. 2012

114.Long-term outcome following imatinib therapy for chronic
       myelogenous leukemia, with assessment of dosage and blood levels:
       the JALSG CML202 study/// K Ohnishi, C Nakaseko, J takeuchi, S
       Fujisawa, T Nagai, H Yamazaki, T Tauchi, K Imai, N Mori, F Yagasaki,
       Y Maeda, N Usui, Y Miyazaki, K Miyamura, H Kiyoi, H Ohtake, T
       Naoe and for the Japan Adult Leukemia Study Group/// Cancer
       Sci 103;1071-1078. 2012

113.Impact of additional chromosomal abnormalities in patients with
       acute promyelocytic leukemia:10-year results of the Japan Adult
       Leukemia Study Group APL97 study./// T Ono, A Takeshita, M
       Iwanaga, N Asou, T Naoe, and R Ohno for he Japan Adult
       Leukemia Study Group/// Haematologica 96(1);174-175, 2011

112.Phase I trial of gemtuzumab ozogamicin in intensive combination
       chemotherapy for relapsed or refractory adult acute myeloid
       leukemia(AML):Japan Adult Leukemia Study
       Group(JALSG)-AML206 study./// N Usui, A Takeshita, C
       Nakaseko, N Dobashi, H Fujita, H Kiyoi, Y Kobayashi, T Sakura, Y
       Yahagi, K Shigeno, C Ohwada, Y Miyazaki, S Ohtake, S Miyawaki, T
       Naoe and K Ohnishi for the Japan Adult Leukemia Study
       Group/// Cancer Science 2011;102:1358-65.

111.A decision analysis of allogeneic hematopoietic stem cell
       transplantation in adult patients with Philadelphia chromosome-
       negative acute lymphoblastic leukemia in first remission who have
       an HLA-matced sibling donor.///S Kako, S Morita, H Sakamaki, H
       Ogawa, T Fukuda, S Takahashi, H Kanamori, M Onizuka, K Iwato, R
       Suzuki, Y Atsuta, T kyo, T Sakura, I Jinnai, J akeuchi, Y Miyazaki, S
       Miyawaki, K Ohnishi, T Naoe and Y Kanda///Leukemia 25:259-265.
       2011

110.Analysis of bacteremia/fungemia and pneumonia accompanying
       acute myelogenous leukemia from 1987 to 2001 in the Japan Adult
       Leukemia Study Group. ///Yoshida M, Akiyama N, Fujita H, Miura
       K, Miyatake J, Handa H, Kito K, Takahashi M, Shigeno K, Kanda Y,
       Hatsumi N, Ohtake S, Sakamaki H, Ohnishi K, Miyawaki S, Ohno R,
       Naoe T./// Int J Hematol. 93:66-73. 2011

109.Pre-transplant imatinib-based therapy improves the outcome of
       allogeneic hematopoietic stem cell transplantation for BCR-ABL-
       positive acute lymphoblastic leukemia.///Mizuta S, Matsuo K,
       Yagasaki F, Yujiri T, Hatta Y, Kimura Y, Ueda Y, Kanamori H, Usui
       N, Akiyama H, Miyazaki Y, Ohtake S, Atsuta Y, Sakamaki H, Kawa
       K, Morishima Y, Ohnishi K, Naoe T, Ohno R.///Leukemia25 :41-7.
       2011

108.BCR-ABL1 mutations in patients with imatinib-resistant
       Philadelphia chromosome-positive leukemia by use of the
       PCR-Invader assay.///Ono T, Miyawaki S, Kimura F, Kanamori H,
       Ohtake S, Kitamura K, Fujita H, Sugiura I, Usuki K, Emi N, Tamaki
       S, Aoyama Y, Kaya H, Naoe T, Tadokoro K, Yamaguchi T, Ohno R,
       Ohnishi K; for the Japan Adult Leukemia Study Group.///Leuk
       Res 35:598-603. 2011

107.Randomized study of induction therapy comparing standard-dose
       idarubicin with high-dose daunorubicin in adult patients with
       previously untreated acute myeloid leukemia: JALSG AML201
       Study.///Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K,
       Usui N, Okumura H, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda
       A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura
       Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T,
       Ohno R.///Blood. 2011;117:2358-2365.

106.A randomized comparison of four courses of standard-dose
       multiagent chemotherapy versus three courses of high-dose
       cytarabine alone in post-remission therapy for acute myeloid
       leukemia in adults: the JALSG AML201 study.///Miyawaki S,
       Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K, Usui N, Sakura T,
       Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane
       T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N,
       Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno
       R.///Blood 117:2366-2372. 2011

105.Prognostic petential of detection of WT1 mRNA level in peripheral
       bolld in adult acute myeloid leukemia.///S Miyawaki, N Hatsumi, T
       Tamaki, T Naoe, K Ozawa, K Kitamura, T Karasuno, K Mitani, Y
       Kodera, T Yamagami, D Koga.///Leukemia & Lymphoma
       51:1855-1861. 2010

104.Intensified consolidation therapy with dose-escalated doxorubicin
       did not improve the prognosis of adults with acute lymphoblastic
       leukemia: the JALSG-ALL97 study.///Jinnai I, Sakura T, Tsuzuki
       M, Maeda Y, Usui N, Kato M, Okumura H, Kyo T, Ueda Y, Kishimoto
       Y, Yagasaki F, Tsuboi K, Horiike S, Takeuchi J, Iwanaga M, Miyazaki
       Y, Miyawaki S, Ohnishi K, Naoe T, Ohno R.///Int J Hematol. 2010
       ;92:490-502.

103.Allogeneic stem cell transplantation versus chemotherapy as
       post-remission therapy for intermediate or poor risk adult acute
       myeloid leukemia: results of the JALSG AML97 study.///Sakamaki
       H, Miyawaki S, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S,
       Kishimoto Y, Miyazaki Y, Asou N, Takahashi M, Ogawa Y, Honda S,
       Ohno R.///Int J Hematol. 2010 ;91:284-92.

102.Comparative analysis of remission induction therapy for high-risk
       MDS and AML progressed from MDS in the MDS200 study of
       Japan Adult Leukemia Study Group///Morita Y, Kanamaru A,
       Miyazaki Y, Imanishi D, Yagasaki F, Tanimoto M, Kuriyama K,
       Kobayashi T, Imoto S, Ohnishi K, Naoe T, Ohno R.///Int J Hematol
       91:97-103. 2010

101.Randomized trial of response-oriented individualized versus fixed-
       schedule induction chemotherapy with idarubisin and cytarabine in
       adult acute myeloid leukemia: the JALSG AML95 study.///Ohtake
       S, Miyawaki S, Kiyoi H, Miyazaki Y, Okumura H, Matsuda S, Nagai T,
       Kishimoto Y, Okada M, Takahashi M, Handa H, Takeuchi J,
       Kageyama S, Asou N, Yagasaki F, Maeda Y, Ohnishi K, Naoe T,
       Ohno R./// Int J Hematol91:276-83. 2010

100.Diagnosis and management of acute myeloid leukemia in adults:
       recommendations from an international expert panel, on behalf of
       the European LeukemiaNet. ///Dohner H, Estey EH, Amadori S,
       Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P,
       Grimwade D, Larson RA, Lo Coco F, Naoe T, Niederwieser D,
       Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Lowenberg B,
       Bloomfield CD.///Blood 21;115(3):453-74. 2010

  99.Recent advances in the treatment of Philadelphia chromosome-
       positive acute lymphoblastic leukemia.///Yanada M, Ohno R, Naoe
       T.///Int J Hematol. 89:3-13.2009

  98.Phase 1/2 clinical study of dasatinib in Japanese patients with
       chronic myeloid leukemia or Philadelphia chromosome-positive
       acute lymphoblastic leukemia.///Sakamaki H, Ishizawa K, Taniwaki
       M, Fujisawa S, Morishima Y, Tobinai K, Okada M, Ando K, Usui N,
       Miyawaki S, Utsunomiya A, Uoshima N, Nagai T, Naoe T, Motoji T,
       Jinnai I, Tanimoto M, Miyazaki Y, Ohnishi K, Iida S, Okamoto S,
       Seriu T, Ohno R.///Int J Hematol. 89:332-41. 2009

  97.Phase I/II study of humanized anti-CD33 antibody conjugated with
       calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory
       acute myeloid leukemia: final results of Japanese multicenter
       cooperative study.///Kobayashi Y, Tobinai K, Takeshita A, Naito K,
       Asai O, DObahsi N, Furusawa S, Saito K, Mitani K, Morishima Y,
       Ogura M, Yoshiba F, Hotta T, Bessho M, Matsuda S, Takeuchi J,
       Miyawaki S, Naoe T, Usui N, Ohno R./// Int J Hematol. 2009; 89:
       460-9.

  96.Management of infection in patients with acute leukemia during
       chmotherapy in Japan: questionnaire analysis by the Japan Adult
       Leukemia Study Group///Fujita H, Yoshida M, Miura K, Sano T,
       Kito K, Takahashi M, Shigeno K, Kanda Y, Akiyama N, Hatsumi N,
       Ohnishi K, Miyawaki S, Naoe T.///In J Hematol.90:191-198.2009

  95.Management of acute promyelocytic leukemia: recommendations
       from an expert panel on behalf of the European
       LeukemiaNet.///Sanz MA, Grimwade D, Tallman MS, Lowenberg B,
       Fenaux P, Estey EH, Naoe T,Lengfelder E, Buchner T, Dohner H,
       Burnett AK, Lo-Coco F.///Blood. 113(9):1875-91. 2009

  94.Prospective monitoring of BCR-ABL1 transcript levels in patients
       with Philadelphia chromosome-positive acute lymphoblastic
       leukaemia undergoing imatinib-combined chemotherapy./// Yanada
       M, Sugiura I, Takeuchi J, Akiyama H, Maruta A, Ueda Y, Usui N,
       Yagasaki F, Yujiri T, Takeuchi M, Nishii K, Kimura Y, Miyawaki S,
       Narimatsu H, Miyazaki Y, Ohtake S,Jinnai I, Matsuo K, Naoe T,
       Ohno R for the Japan Adult Leukemia Study Group.///Brit J
       Haematol.143:503-510.2008

  93.Diagnosis of acute myeloid leukemia according to the WHO
       classification in the Japan Adult Leukemia Study Group AML-97
       protocol.///Wakui M, Kuriyama K, Miyazaki Y, Hata T, Taniwaki M,
       Ohtake S, Sakamaki H, Miyawaki S, Naoe T, Ohno R, Tomonaga
       M.///Int J Hematol 87:144-151.2008

  92.Karyotype at diagnosis is the major prognostic factor predicting 
       relapse-free survival for patients with Philadelphia chromosome-
       positive acute lymphoblastic leukemia treated with imatinib-
       combined chemotherapy.///M Yanada, J Takeuchi, I Sugiura, H 
       Akiyama, N Usui, F Yagasaki, K Nishii, Y Ueda,M Takeuchi, S
       Miyawaki, A Maruta, H Narimatsu, Y Miyazaki, S Ohtake, I Jinnai, K
       Matsuo, T Naoe, R Ohno, for the Japan Adult Leukemia Study
       Group.///Haematologica 93:287-290. 2008

  91.Phase I Traial of FLAGM with High Doses of Cytosine Arabinoside
       for Relapsed, Refractory Acute Myeloid Leukemia: Study of the
       Japan Adult Leukemia Study Group(JALSG)///Miyawaki S, Kawai
       Y, Takeshita A, Komatsu N, Usui N, Arai Y, Ishida F, Morii T, Kano
       Y, Ogura M, Doki N, Ohno R.///In J Hematol. 86: 343-347.2007

  90.A randomized study with or without intensified maintenance
       chemotherapy in patients with acute promyelocytic leukemia who
       have become negative for PML-RARα transcript after
       consolidation therapy:The Japan Adult Leukemia Study
       Group(JALSG) APL97 study./// Asou N, Kishimoto Y, Kiyoi H,
       Okada M, Kawai Y, Tsuzuki M, Horikawa K, Matsuda M, Shinagawa
       K, Kobayashi T, Ohtake S, Nishimura M, Takahashi M, Yagasaki F,
       Takeshita A, Kimura Y, Iwanaga M, Naoe T, and Ohno R, for the
       Japan Adult Leukemia Study Group///Blood 110:59-66. 2007

  89.Prediction of risk of disease recurrence by genome-wide cDNA
       microarryay analysis in patioents with Philadelphia chromosome-
       positive acute lymphoblastic leukemia treated with imatinib-
       combined cnemotherapy.///Zembutsu H, Yanada M, Hishida A,
       Katagiri T, Tsuruo T, Sugiura I, Takeuchi J, Usui N, Naoe T,
       Nakamura Y, Ohno R.///Int J Oncol. 31:313-22.2007

  88.Severe hemorrhagic complications during remission induction
       therapy for acute promyelocytic leukemia: incidence, risk factors,
       and influence on outcome.///Yanada M, Matsushita T, Asou N,
       Kishimoto Y, Tsuzuki M, Maeda Y, Horikawa K, Okada M, Ohtake S,
       Yagasaki F, Matsumoto T, Kimura Y, Shinagawa K, Iwanaga M,
       Miyazaki Y, Ohno R, Naoe T.///Eur J Haematol. 78(3):213-9.2007

  87.Clinical features and outcome of T-lineage acute lymphoblastic 
       leukemia in adults: a low initial white blood cell count, as well as a
       high count predict decreased survival rates.///Yanada M, Jinnai I,
       Takeuchi J, Ueda T, Miyawaki S, Tsuzuki M, Hatta Y, Usui N, Wada
       H, Morii T, Matsuda M, Kiyoi H, Okada M, Honda S, Miyazaki Y,
       Ohno R, Naoe T./// Leuk Res 31(7):907-14.2007

  86.Imatinib combined chemotherapy for Philadelphia chromosome-
       positive acute lymphoblastic leukemia: major challenges in current
       practice.///Yanada M, Naoe T.///Leuk & Lymph.Y 47:1747-1753,
       2006.

  85.High Complete Remission Rate and Promising Outcome by
       Combination of Imatinib and Chemotherapy for Newly Diagnosed
       BCR-ABL-positive Acute Lymphoblastic Leukemia: A Phase 2
       Study by the Japan Adult Leukemia Study Group. ///Yanada M,
       Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F,Kobayashi T,
       Ueda Y, Takeuchi M, Miyawaki S, Maruta A, Emi N, Miyazaki
       Y,Ohtake S, Jinnai I, Matsuo K, Naoe T, and Ohno R./// J Clin
       Oncol.24:460 -466. 2006

  84.A Randomized, Postremission Comparison of Four Courses of
       Standard-Dose Consolidation Therapy without Maintenance
       Therapy versus Three Courses of Standard-Dose Consolidation
       with Maintenance Therapy in Adults with Acute Myeloid Leukemia:
       The Japan Adult Leukemia Study Group AML97 Study///
       Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani 
       K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Matsushima T,
       Takahashi M, Ogawa Y, Honda S, Ohno R,and for the Japan
       Adult Leukemia Study Group///Cancer 104. 2726 -34. 2005

  83.Clinical characteristics and prognostic implications of NPM1
       mutations in acute myeloid leukemia. ///Suzuki T, Kiyoi H, Ozeki K,
       Tomita A, Yamaji S, Suzuki R, Kodera Y, Miyawaki S, Asou N,
       Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Nishimura M,
       Motoji T, Shinagawa K, Takeshita A, Ueda R, Kinoshita T, Emi N,
       Naoe T. ///Blood 106: 2854-2861. 2005

  82.A randomized study with or without maintenance/intensification
       chemotherapy in newly diagnosed patients with acute
       promyelocytic leukemia: the JALSG APL97 study. /// Naoe T,
       Asou N, Ohno R for the Japan Adult Leukemia Study Group
       (JALSG). ///Haematologica reports 1: 70-71. 2005

  81.Comparison of graft-versus-host-disease and survival after
       HLA-identical sibling bone marrow transplantation in ethnic
       populations./// Hakumei Oh, Fausto R. Loberiza, Jr, Mei-jie Zhang,
       Olle Ringden, Hideki Akiyama, Takayoshi Asai, Shuichi Miyawaki,
       Shinichiro Okamoto, Mary M. Horowitz, Joseph H. Antin, Asad
       Bashey, Jennifer M. Bird, Matthew H. Carabasi, Joseph W. Fay,
       Robert Peter Gale, Roger H. Giller, John M. Goldman, Gregory A.
       Hale, Richard E. Harris, Jean Henslee-Downey, Hans-Jochem Kolb,
       Mark R. Litzow, Philip L. McCarthy, Steven M. Neudorf, Derek S.
       Serna, Gerard Socie, Pierre Tiberghien, and A. John
       Barrett///Blood  105(4):1408-1416. 2005

  80.Biological and clinical significance of the FLT3 transcript level in
       acute myeloid leukemia./// Ozeki K, Kiyoi H, Hirose Y, Iwai M,
       Ninomiya M, Kodera Y, Miyawaki S, Kuriyama K, Shimazaki C,
       Akiyama H, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Ueda
       R, Ohno R, Emi N, Naoe T./// Blood. 103:1901-1908. 2004

  79.Combination of intensive chemotherapy and imatinib can rapidly
       induce high-quality complete remission for a majority of patients
       with newly diagnosed BCR-ABL positive acute lymphoblastic
       leukemia.///Towatari M, Yanada M, Usui N, Takeuchi J, Sugiura I,
       Takeuchi M, Yagasaki F, Kawai Y, Miyawaki S, Ohtake S, Jinnai I,
       Matsuo K, Naoe T, Ohno R.///Blood.;104(12):3507-12. 2004

  78.The recent JALSG study for newly diagnosed patients with acute
       promyelocytic leukemia (APL).///Ohno R, Asou N; Japan Adult
       Leukemia Study Group.///Ann Hematol. 83 Suppl 1:S77-8. 2004

  77.Multicenter prospective study of interferon alpha versus allogeneic
       stem cell transplantation for patients with new diagnoses of
       chronic myelogenous leukemia.///Ohnishi K, Ino A, Kishimoto Y,
       Usui N, Shimazaki C, Ohtake S, Taguchi H, Yagasaki F, Tomonaga
       M, Hotta T, Ohno R; Japan Adult Leukemia Study Group.///Int J
       Hematol. 79(4):345-53. 2004

  76.Treatment of acute promyelocytic leukemia: strategy toward
       further increase of cure rate./// Ohno R, Asou N, Ohnishi K.///
       Leukemia 17(8):1454-1463, 2003.

  75.Prediction of response to imatinib by cDNA microarray analysis.
       ///R Ohno, Y Nakamura./// Seminars in Hematology.40(2):42-49,
       2003

  74.The percentage of myeloperoxidase-positive blast cells is a strong
       independent prognostic factor in acute myeloid leukemia, even in
       the patients with normal karyotype.///Matsuo T, Kuriyama K,
       Miyazaki Y, Yoshida S, Tomonaga M, Emi N, Kobayashi T, Miyawaki
       S, Matsushima T, Shinagawa K, Honda S, Ohno R; Japan Adult
       Leukemia Study Group.///Leukemia. 17(8):1538-43.2003

  73.Prognosis and prognostic factors for patients with chronic myeloid
       leukemia: nontransplant therapy.///Hasford J, Pfirrmann M,
       Hehlmann R, Baccarani M, Guilhot F, Mahon FX, Kluin-Nelemans
       HC, Ohnishi K, Thaler J, Steegmann JL; Collaborative CML
       Prognostic Factors Project Group./// Semin Hematol. 40(1): 4-12.
       Review,2003

  72.Possible dominant-negative mutation of the SHIP gene in acute
       myeloid leukemia./// Luo JM, Yoshida H, Komura S, Ohishi N, Pan
       L, Shigeno K, Hanamura I, Miura K, Iida S, Ueda R, Naoe T,Akao Y,
       Ohno R, Ohnishi K./// Leukemia. 17(1): 1-8,2003

  71.Dual mutations in the AML1 and FLT3 genes are associated with
       leukemogenesis in acute myeloblastic leukemia of the M0
       subtype./// N Matsuno, M Osato, N Yamashita, M Yanagida, T
       Nanri, T Fukushima, T Motoji, S Kusumoto, M Towartari, R Suzuki,
       T Naoe, K Nishii, K Shigesada, R Ohno, H Mitsuya, Y Ito and N
       Asou./// Leukemia 17:2492-2499, 2003

  70.Cytogenetic heterogeneity of acute myeloid leukaemia(AML)with
       trilineage dysplasia:Japan Adult Leukaemia Study Group-AML 92
       study./// Y.Miyazaki, K.Kuriyama, S.Miyawaki, S.Ohtake,
       H.Sakamaki, T.Matsuo, N.Emi, T.Kobayashi, T.Matsushima,
       K.Shinagawa, R.Ohno and M.Tomonaga for the Japan Adult
       Leukemia Study Group./// Br J Haematology 120:56-62,2003

  69.Rapid screening of leukemia fusion transcripts in acute leukemia by
       Real-time PCR.///Osumi K, Fukui T, Kiyoi H, Kasai M, Kodera Y,
       Kudo K, Kato K, Matsuyama M, Naito K, Tamimoto M, Hirai H,
       Saito H, Ohno R, Naoe T. ///Leuk Lymphoma 43: 2291-2299. 2002

  68.Efficacy of granulocyte colony-stimulating factor in the treatment
       of acute myelogenous leukaemia: a multicentre randomized
       study.///Usuki K, Urabe A, Masaoka T, Ohno R, Mizoguchi H,
       Hamajima N, Miyazaki T, Niitsu Y, Yoshida Y, Miura A, Shibata A,
       Abe T, Miura Y, Ikeda Y, Nomura T, Nagao T, Saitou H, Shirakawa
       S, Ohkuma M, Matsuda T, Nakamura T, Horiuchi A, Kuramoto A,
       Kimura I, Irino S, Niho Y, Takatsuki K, Tomonaga M, Uchino H,
       Takaku F; Gran AML Study Group./// Br J Haematol. 116(1):
       103-12,2002

  67.Prognostic significance of the null genotype of glutathione
       S-transferase-T1 in patients with acute myeloid leukemia:
       increased early death after chemotherapy.///Naoe T, Tagawa Y,
       Kiyoi H, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Kusumoto S,
       Shimazaki C, Saito K, Akiyama H, Motoji T, Nishimura M, Shinagawa
       K, Ueda R, Saito H, Ohno R./// Leukemia. 16(2): 203-8, 2002

  66.Report of the fifteenth international symposium of the foundation
       for promotion of cancer research: new horizons in the diagnosis
       and treatment of hematological malignancies based on molecular
       genetic features.///Multani PS, Tobinai K, Kakizoe T, Armitage JO,
       Ohno R, Sugimura T./// Jpn J Clin Oncol. 32(9): 371-85,2002

  65.Prediction of sensitivity to STI571 among chronic myeloid leukemia
       patients by genome-wide cDNA microarray analysis./// Kaneta Y,
       Kagami Y, Katagiri T, Tsunoda T, Jin-nai I, Taguchi H, Hirai H,
       Ohnishi K, Ueda T, Emi N, Tomida A, Tsuruo T, Nakamura Y, Ohno
       R./// Jpn J Cancer Res. 93(8): 849-56,2002

  64.Arsenic trioxide therapy for relapsed or refractory Japanese
       patients with acute promyelocytic leukemia: need for careful
       electrocardiogram monitoring./// Ohnishi K, Yoshida H, Shigeno K,
       Nakamura S, Fujisawa S, Naito K, Shinjo K, Fujita Y, Matsui H,
       Sahara N, Takeshita A, Satoh H, Terada H, Ohno R./// Leukemia.
       16(4): 617-22,2002

  63.Clinicopathological and prognostic characteristics of
       CD56-negative multiple myeloma.///Sahara N, Takeshita A,
       Shigeno K, Fujisawa S, Takeshita K, Naito K, Ihara M, Ono T,
       Tamashima S, Nara K, Ohnishi K, Ohno R./// Br J Haematol.
       117(4): 882-5,2002

  62.Prediction of chemosensitivity for patients with acute myeloid
       leukemia, according to expression levels of 28 genes selected by
       genome-wide complementary DNA microarray analysis.///Okutsu
       J, Tsunoda T, Kaneta Y, Katagiri T, Kitahara O, Zembutsu H,
       Yanagawa R, Miyawaki S, Kuriyama K, Kubota N, Kimura Y, Kubo K,
       Yagasaki F, Higa T, Taguchi H, Tobita T, Akiyama H, Takeshita A,
       Wang YH, Motoji T, Ohno R, Nakamura Y./// Mol Cancer Ther.
       1(12):1035-42,2002

  61.Induction therapy by frequent administration of doxorubicin with
       four other drugs, followed by intensive consolidation and
       maintenance therapy for adult acute lymphoblastic leukemia: the
       JALSG-ALL93 study./// Takeuchi J, Kyo T, Naito K, Sao H,
       Takahashi M, Miyawaki S, Kuriyama K, Ohtake S, Yagasaki F,
       Murakami H, Asou N, Ino T, Okamoto T, Usui N, Nishimura M,
       Shinagawa K, Fukushima T, Taguchi H, Morii T, Mizuta S, Akiyama
       H, Nakamura Y, Ohshima T, Ohno R./// Leukemia
       16(7):1259-1266,2002

  60.Activating mutation of D835 within the activation loop of FLT3 in
       human hematologic malignancies.///Yamamoto Y, Kiyoi H, Nakano
       Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki
       F, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T,
       Shinagawa K,Takeshita A, Saito H, Ueda R, Ohno R, and Naoe T.
       ///Blood 97: 2434-2439. 2001

  59.Clinicopathologic characteristics of leukemia in Japanese children
       and young adults./// Horibe K, Tsukimoto I, Ohno R./// Leukemia
       15(8):1256-61,2001

  58.Analysis of prognostic factors in newly diagnosed patients with
       acute promyelocytic leukemia: the APL92 study of the Japan
       Adult Leukemia Study Group (JALSG)./// Asou N, Adachi K,
       Tamura U, Kanamaru A, Kageyama S, Hiraoka A, Omoto E,
       Akiyama H, Tsubaki K, Saito K, Kuriyama K, Oh H, Kitano K,
       Miyawaki S, Takeyama U, Yamada O, Nishikawa K, Takahashi M,
       Matsuda S, Ohtake H, Ohno R./// Cancer Chemother Pharmacol
       48 Suppl 1:S65-71,2001

  57.Morphological diagnosis of the Japan Adult Leukemia Study Group
       acute myeloid leukemia protocols: Central review. /// K.Kuriyama,
       M.Tomonaga, T.Kobayashi, J.Takeuchi, T.Ohshima, S.Furusawa,
       K.Saitoh, R.Ohno for the Japan Adult Leukemia Study Group. ///
       Inter J Hematol 73(1):93-99,2001

  56. Prolongation of the QT interval and ventricular tachycardia in patients
       treated with arsenic trioxide for acute promyelocytic leukemia. ///
       Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K,
       Shinjyo K, Fujita Y, Matsui H, Takeshita A, Sugiyama S, Satoh H,
       Terada H, Ohno R /// Ann Intern Med 033:881-886, 2000

  55.Prognostic value of p53 gene mutations and the product
       expression in de novo acute myeloid leukemia. ///Nakano Y, Naoe
       T, Kiyoi H, Kitamura K, Minami S, Miyawaki S, Asou N, Kuriyama K,
       Kusumoto S, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji
       T, Shinagawa K, Saito H, Ohno R./// Eur J Haematol 65: 23-31.
       2000

  54.Poor clinical significance of p53 gene polymorphism in acute
       myeloid leukemia. /// Nakano Y, Naoe T, Kiyoi H, Kunishima S,
       Minami S, Miyawaki S, Asou N, Kuriyama K, Saito H, Ohno
       R.///Leuk Res 24:349-352. 2000,

  53.Allogeneic bone marrow transplantation improves the outcome
       of de novo AML with trilineage dysplasia(AML-TLD)./// Taguchi J,
       Miyazaki Y, Yoshida S, Fukushima T, Moriuchi Y, Jinnai I, Matsuo T,
       Kuriyama K, Tomonaga M./// Leukemia 14(11):1861-6,2000

  52.How high can we increase complete remission rate in adult acute
       myeloid leukemia?/// Ohno R./// Int J Hematol 72(3):272-9,2000

  51.Trisomy 11 acute myeloid leukemia: 5 additional cases from the
       Japan Adult Leukemia Study Group AML-92 and AML-95
       databases./// Suzuki A, Ohyashiki K, Kimura Y, Yamada H, Sano F,
       Miyawaki S, Kuriyama K, Ohno R; Japan Adult Leukemia Study
       Group./// Int J Hematol 72:466-9,2000

  50.Combination chemotherapy with risk factor-adjusted dose
       attenuation for high-risk myelodysplastic syndrome and resulting
       leukemia in the multicenter study of the Japan Adult Leukemia
       Study Group(JALSG): Results of an interim analysis.///
       T.Okamoto, A.Knamaru, C.Shimazaki, T.Motoji, Y.Takemoto,
       M.Takahashi, T.Fukushima, A.Takeshita, S.Kusumoto, Y.Kishimoto,
       S.Yorimitsu, K.Tsukuda, N.Uike, N.Arima, R.Ohno. /// Inter J
       Hematol 72(2):200-205,2000

 49.Trisomy 10 in Acute Myeloid Leukemia: Three Additional Cases
       from the Database of the Japan Adult Leukemia Study Group
       (JALSG) AML-92 and AML-95. /// A.Suzuki, Y.Kimura,
       K.Ohyashiki, K.Kitano, S.Kageyama, M.Kasai, S.Miyawaki, and
       R.Ohno (Japan Adult Leukemia Study Group). /// Cancer Genet
       Cytogenet 120(2):141-143,2000

 48.Prognostic significance of the cell inhibitor p27 kip1 in acute
       myeloid leukemia. ///T.Yokozawa, M.Towatari, H.Iida, K.Takeyama,
       M.Tanimoto, H.Kiyoi, T.Motoji, N.sou, K.Saito, M.Takeuchi,
       Y.Kobayashi, S.Miyawaki, Y.Kodera, R.Ohno, H.Saito and T.Naoe for
       Japan Adult Leukemia Study Group. /// Leukemia 14:28-33,2000

 47.Quantitative expression of erythropoietin receptor(EPO-R) on
       acute leiukaemia cells: relationships between the amount of EPO-R
       and CD phenothpes,in vitro proliferative response,the amount of
       other cytokine receptors and clinical prognosis. /// A.Takeshita,
       K.Takeshita, M.Higuchi, S.Miyawaki, Y.Takemoto, Y.Kishimoto,
       K.Saito, H.Taguchi, K.Kuriyama, Y.Kimura, N.Asou, M.Takahashi,
       T.Hotta, A.Kanamaru, R.Ueda, R.Ohno for the Japan Adult
      Leukemia Study Group. /// Br J Haematol 108:55-63,2000

 46.Prognostic implication of FLT3 and N-RAS gene mutations in
       acute myeloid leukemia. ///Kiyoi H, Naoe T, Nakano Y, Yokota S,
       Minami S, Miyawaki S, Asou N, Kuriyama K, Jinnai I, Shimazaki C,
       Akiyama H, Saito K, Oh H, Motoji T, Omoto E, Saito H, Ohno R,
       Ueda R./// Blood 93: 3074-3080. 1999

 45.Molecular evolution of acute myeloid leukaemia in relapse: unstable
       N-ras and FLT3 genes compared with p53 gene. /// Nakano Y.
       Kiyoi H. Miyawaki S. Asou N. Ohno R. Saito H. Naoe T.///Br J
       Haematol 104: 659-664. 1999.

 44.Infectious complications during remission induction therapy in 577
       patients with acute myeloid leukemia in the Japan Adult Leukemia
       Study Group studies between 1987 and 1991. ///M.Yoshida,
       K.Tsubaki, T.Kobayashi, M.Tanimoto, K.Kuriyama, H.Murakami,
       S.Minami, A.Hiraoka, I.Takahashi, T.Naoe, N.Asou, S.Kageyama,
       M.Tomonaga, H.Saito, R.Ohno, for the Japan Adult Leukemia Study
       Group. /// Inter J Hematol 70:261-267,1999

 43.No beneficial effect from addition of etoposide to daunorubicin,
       cytarabine, and 6- mercaptopurine in individualized induction
       therapy of adult acute myeloid leukemia: the JALSG-AML92
       study. /// S.Miyawaki, M.Tanimoto, T.Kobayashi, S.Minami,
       J.Tamura, E.Omoto, K.Kuriyama, K.Hatake, K.Saito, A.Kanamaru,
       H.Oh, S.Ohtake, N.Asou, H.Sakamaki, O.Yamada, I.Jinnnai, K.Tsubaki,
       K.Takeyama, A.Hiraoka, S.Matsuda, M.Takahashi, C.Shimazaki,
       K.Adachi, S.Kageyama, T.Sakura, R.Ohno, for the Japan Adult
       Leukemia Study Group. ///Inter J Hematol 70:97-104,1999

 42.Comparison of leukopenia between cytarabine and behenoyl
       cytarabine in JALSG AML-89 consolidation therapy.
       ///S.Miyawaki, T.Kobayashi, M.Tanimoto, K.Kuriyama, H.Murakami,
       M.Yoshida, S.Minami, K.Minato, K.Tsubaki, E.Omoto, H.Oh, I.Jinnai,
       H.Sakamaki, A.Hiraoka, A.Kanamaru, I.Takahashi, K.Saito, T.Naoe,
        O.Yamada, N.Asou, S.Kageyama, N.Emi, T.Ueda, M.Tomonaga,
       H.Saito, R.Ueda, R.Ohno, for the Japan Adult Leukemia Study
       Group. ///Inter J Hematol 70:56-57,1999

 41.Granulocyte colony-stimulating factor, granulocyte-macrophage
       colony-stimulating factor and macrophage colony-stimulating factor
       in the treatment of acute myeloid leukemia and acute lymphoblastic
       leukemia.///R.Ohno.///Leuk Res
       22(12):1143-54,1998

 40.Multicenter cooperative study group in hematology in Japan: the
       10-year history and role of the Japan Adult Leukemia Study Group
       in Japan./// Ohno R./// Int J Hematol67(3):213-9,1998

 39.Cooperative oncology groups in Japan: experience from the Japan
       Adult Leukemia Study Group./// Ohno R./// Cancer Chemother
       Pharmacol42 Suppl:S93-7,1998

 38.Response-oriented individualized indeuction therapy followed by
       intensive consolidation and maintenance for adult patients with
       acute lymphoblastic leukemia: Thed ALL-87 Study of the Japan
       Adult Leukemia Study Group. /// M.tanimoto, S.Miyawaki, T.Ino,
       T.Kyo, H.Sakamaki, T.Naoe, A.Hiraoka, N.Asou, T.Ohshima,
       K.Tsubaki, K.Kuriyama, T.Ueda, S.MInami, K.Okabe,H.Saito,
       H.Murakami, M.Hirano, H.Dohy, Y.Onozawa, H.Suzuki, R.Ohno. ///
       Inter J Hematol 68:421-429,1998

 37.Response-oriented individualized induction therapy with six drugs
       followed by four courses of intensive consolidation, 1 year
       maintenance and intensification therapy: the ALL90 study of the
       Japan Adult Leukemia Study Group. /// T.Ueda, S.Miyawaki,
       N.Asou, Y.Kuraishi, A.Hiraoka, K.Kuriyama, S.Minami, T.Ohsima,
       T.Ino, J.Tamura, A.Kanamaru, K.Nishikawa, M.Tanimoto, H.OH,
       K.saito, K.Nagata, T.Naoe, O.Yamada, Y.Urasaki, T.Sakura, R.Ohno.
       /// Inter J Hematol 68:279-289,1998

 36.Chemotherapy vs HLA-indentical sibling bone marrow transplants
       for adults with acute lymphoblastic leukemia in first remission. ///
       H.Oh, RP Gale, M-J Zhang, JR Passweg, T Ino, H Murakami, R
       Ohno, PA Rowlings, KA Sobocinski, M Tanimoto, M Tomonaga, DJ
       Weisdorf and MM Horowitz. /// Bone Marrow Transplant.
       22:253-257,1998

 35.Analysis of prognostic factors in newly diagnosed acute
       promyelocytic leukemia treated with all-trans retinoic acid and
       chemotherapy. /// N.Asou, K.Adachi, J.Tamura, A.Kanamaru,
       S.Kageyama, A.Hiraoka, E.Omoto, H.Akiyama, K.Tsubaki, K.Saito,
       K.Kuriyama, H.Oh, K.Kitano, S.Miyawaki, K.Takeyama, O.Yamada,
       K.Nishikawa, M.Takahashi, S.Matsuda, S.Ohtake, H.Suzushima,
       N.Emi, R.Ohno and the Japan Adult Leukemia Study Group
       (JALSG)./// Journal of Clinical Oncology 16(1):78-85,1998

 34.Internal trandem duplication of FLT3 associated with leukocytosis
       in acute promyelocytic leukemia. /// H.Kiyoi, T.Naoe, S.Yokota,
       M.Nakao, S.Minami, K.Kuriyama, A.Takeshita, K.Saito, S.Hasegawa,
       S.Shimodaira, J.tamura, C.Shimazaki, K.Matsue, H.Kobayashi,
       N.Arima, R.Suzuki, H.Morishita, H.Saito, R.Ueda, R.Ohno and the
       Leukemia Study Group of the Ministry of Health and
       Welfare(Kohseisho). /// Leukemia 11:1447-1452,1997

 33.All-trans retinoic acid therapy for newly diagnosed acute
       promyelocytic leukemia: comparison with intensive chemotherapy.
       /// N.Asou, K.Adachi, J.Tamura, A.Kanamaru, S.Kageyama,
       A.Hiraoka, E.Omoto, H.Sakamaki, K.Tsubaki, K.Saito, R.Ohno and
       the Japan Adult Leukemia Study Group (JALSG). /// Cancer
       Chemother Pharmacol 40:S30-S35,1997

 32.Human urinary macrophage colony-stimulating factor reduces the
       incidence and duration of febrile neutropenia and shortens the
       period required to finish three courses of intensive consolidation
       therapy in acute myeloid leukemia:a double-blind controlled study.
       /// R.Ohno, S.Miyawaki, K.Hatake, K.Kuriyama, K.Saito,
       A.Kanamaru, T.Kobayashi, Y.Kodera, K.Nishikawa, S.Matsuda,
       O.Yamada, E.Omoto, H.Takeyama, K.Tsukuda, N.Asou, M.Tanimoto,
       H.Shiozaki, M.Tomonaga, T.Masaoka, Y.Miura, F.Takaku, Y.Ohashi
       and K.Motoyoshi. /// Journal of Clinical Oncology
       15(8):2954-2965,1997

 31.Treatment with a new synthetic retinoid, Am80,of acute
       promyelocytic leukemia relapsed from complete remission induced
       by all-trans retinoic acid. /// T.Tobita, A.Takeshita, K.Kitamura,
       K.Ohnishi, M.Yanagi, A.Hiraoka, T.Karasuno, M.Takeuchi, S.Miyawaki,
       R.Ueda, T.Naoe and R.Ohno. /// Blood90(3):967-973,1997

 30.Morpholosgical subtyping of acute myeloid leukemia with
       maturation (AML-M2): homogeneous pink-coloared cytoplasm of
       mature neutrophils is most characteristic of AML-M2 with t(8;21).
       /// H.Nakamura, K.Kuriyama, N.Sadamori, M.Mine, T.Itoyama,
       I.Sasagawa, K.Matsumoto, Y.Tsuji, N.Asou, S.I.Kageyama,
       H.Sakamaki, N.Emi, R.Ohno and M.Tomonaga. ///
       Leukemia11:651-655,1997

 29.Case-control study of leukemia and diagnostic radiation exposure.
       /// H.Yuasa, N.Hamajima, R.Ueda, R.Ohno, N.Asou, A.Utsunomiya,
       M.Ogura, N.Takigawa, T.Ueda, A.Hiraoka, S.Matsuda, Y.Kuraishi,
       K.Nishikawa, N.Uike, A.Takeshita, Y.Takemoto, C.Shimazaki,
       H.Sakamaki, T.Ino, T.Matsushima, K.Kuriyama, H.Hirai, T.Naoe,
       K.Tsubaki, M.Takahashi, K.Takeyama, Y.Morishima, K.Itoh. /// Inter
       J Haematol 65:251-261,1997

 28.Application of fluorescence in situ hybridization to detect residual
       leukemic cells with 9;22 and 15;17 translocations. /// K.Tanaka,
       M.Arif, M.Eguchi, T.S.Kumaravel, R.Ueda, R.Ohno, K.Iwato, T.Kyo,
       H.Dohy and N.Kamada. /// Leukemia11:436-440,1997

 27.Inactivation of multiple tumor-suppressor genes involved in
       negative regulation of the cell cycle, MTS1/p161NK4A CDKN2,
       MTS2/p151NK4B, p53, and Rb genes in primary lymphoid
       malignancies. /// A.Hangaishi, S.Ogawa, N.Imamura, S.Miyawaki,
       Y.Miura, N.Uike, C.Shimazaki, N.Emi, K.Takeyama, S.Hirosawa,
       N.Kamada, Y.Kobayashi, Y.Takemoto, T.Kitani, K.Toyama, S.Ohtake,
       Y.Yazaki, R.Ueda, H.Hirai. /// Blood 87:4949-58,1996

 26.Expression of costimulatory molecules in human leukemias. ///
       N.Hirano, T.Takahashi, T.Takahashi, S.Ohtake, K.Hirashima, N.Emi,
       K.Saito, M.Hirano, K.Shinohara, M.Takeuchi, F.Taketazu, S.Tsunoda,
       M.Ogura, M.Omine, T.Sito, Y.Yazaki, R.Ueda, H.Hirai. ///
       Leukemia10:1168-76,1996

 25.Successful treatment of relapse of acute promyelocytic leukemia
       with a new synthetic retinoid, Am80. /// A.Takeshita, Y.Shibata,
       K.Shinjo, M.Yanagi, T.Tobita, K.Ohnishi, S.Miyawaki, K.Shudo and
       R.Ohno. /// Annals of Internal Medicine 124:893-896,1996

 24.Randomized trials between behenoyl cytarabine and cytarabine in
       combination induction and consolidation therapy, and with or
       without ubenimex after maintenance/intensification therapy in
       adult acute myeloid leukemia. /// T.Kobayashi, S.Miyawaki,
       M.Tanimoto, K.Kuriyama, H.Murakami, M.Yoshida, S.Minami,
       K.Tsubaki, E.Ohmoto, H.Oh, I.Jinnai, H.Sakamaki, A.Hiraoka,
       A.Kanamaru, I.Takahashi, K.Saito, T.Naoe, O.Yamada, N.Asou,
       S.Kageyama, N.Emi, A.Matsuoka, M.Tomonaga, H.Saito, R.Ueda, and
       R.Ohno for the Japan Adult Leukemia Study Group(JALSG). ///
       Journal of Clinical Oncology 14:204-213,1996

 23.Recent progress in the treatment of adult acute leukemia in
       Japan. /// R.Ohno for the Japan Adalt Leukemia Study Group
       (JALSG). /// Cancer Chemotherapy 10:73-79,1995

 22.Significant reduction of medical costs by differentiation therapy
       with all-trans retinoic acid during remission induction of newly
       diagnosed patients with acute promyelocytic leukemia. ///
       A.Takeshita, H.Sakamaki, S.Miyawaki, T.Kobayashi, K.Kuriyama,
       O.Yamada, H.Oh, T.Takenaka, N.Asou, R.Ohno and the Japan Adult
       Leukemia Sutdy Group (JALSG). /// Cancer76:602-608,1995

 21.Isoforms of PML-retinoic acid receptor alpha fused transcripts
       affect neither clinical features of acute promyelocytic leukemia
       nor prognosis after treatment with all-trans retinoic acid. ///
       H.Fukutani, T.Naoe, R.Ohno, H.Yoshida, S.Miyawaki, C.Simazaki,
       T.Miyake, Y.Nakayama, H.Kobayashi, S.Goto, A.Takeshita,
       S.Kobayashi, Y.Kato, K.Shiraishi, M.Sasada, S.Ohtake, H.Murakami,
       M.Kobayashi, N.Endo, H.Shindo, K.Matsushita, S.Hasegawa, K.Tsuji,
       Y.Ueda, N.Tominaga, H.Furuya, Y.Inoue, J.Takeuchi, H.Morishita,
       H.Iida, and the Leukemia Study Group of the Ministry of Health
       and Welfare(Kohseisho). /// Leukemia9:1478-1482,1995

 20.A randomized trial comparing interferon-alpha with busulfan for
       newly diagnosed chronic myelogenous leukemia in chronic phase.
       /// K.Ohnishi, R.Ohno, M.Tomonaga, N.Kamada, K.Onozawa,
       A.Kuramoto, H.Dohy, H.Mizoguchi, S.Miyawaki, K.Tsubaki, Y.Miura,
       M.Omine, T.Kobayashi, T.Naoe, T.Ohshima, K.Hirashima, S.Ohtake,
       I,Takahashi, Y.Morishima, K.Naito, N.Asou, M.Tanimoto, A.Sakuma,
       K.Yamada and the Kouseisho Lukemia Study Group. /// Blood
       86:906-916,1995

 19.All-trans retinoic acid for the treatment of newly diagnosed acute
       promyelocytic leukemia. /// A.Kanamaru and R.Ohno. /// Blood
       86:1644-45,1995

 18.Prognostic significance of the RT-PCR assay of PML-RARA
       transcripts in acute promyelocytic leukemia. ///H.Fukutani,
       T.Naoe, R.Ohno , H.Yoshida, H.Kiyoi, S.Miyawaki, H.Morishita,
       F.Sano, H.Kamibayashi, K.Matsue, T.Miyake, S.Hasegawa, Y.Ueda,
       T.Kato, H.Kobayashi, C.Shimazaki, M.Kobayashi, R.Kurane,
       H.Sakota, K.Masaki, T.Wakayama, K.Tohyama, Y.Nonaka, H.Natori
       and the leukemia Study Group of the Ministry of Health and
       Welfare (Kouseisho). ///Leukemia9:588-593,1995

 17.All-trans retinoic acid for the treatment of newly diagnosed acute
       promyelocytic leukemia. /// A.Kanamaru, Y.Takemoto, M.Tanimoto,
       H.Murakami, N.Asou, T.Kobayashi, K.Kuriyama, E.Ohmoto,
       H.Sakamaki, K.Tsubaki, A.Hiraoka, O.Yamada, H.Oh, K.Saito,
       S.Matsuda, K.Minato, T.Ueda, R.Ohno and the Japan Adult
       Leukemia Study Group (JALSG). /// Blood 85:1202-1206,1995

 16.G-CSF in the treatment of acute myeloid leukemia:is it safe? ///
       R.Ohno. /// Leukemia and Lymphoma 11(Suppl.2):15-19.1994

 15.All-trans retinoic acid therapy in relapsed/refractory or newly
       diagnosed acute promyelocytic leukemia(APL) in Japan. ///
       R.Ohno, K.Ohnishi, A.Takeshita, M.Tanimoto, H.Murakami,
       A.Kanamaru, N.Asou, T.Kobayashi, K.Kuriyama, E.Ohmoto,
       H.Sakamaki, K.Tsubaki, A.Hiraoka, O.Yamada, H.Oh, S.Furusawa,
       S.Matsuda and T.Naoe. /// Leukemia 8(suppl.3):S64-S69,1994

 14.Differentiation therapy of myelodysplastic syndromes with retinoic
       acid. ///R.Ohno. /// Leukemia & Lymphoma 14:401-409,1994

 13.A double-blind controlled study of granulocyte colony-stimulating
       factor started two days before induction chemotherapy in
       refractory acute myeloid leukemia. /// R.Ohno, T.Naoe,
       A.Kanamaru, M.Yoshida, A.Hiraoka, T.Kobayashi, T.Ueda, S.Minami,
       Y.Morishima, Y.Saito, S.Furusawa, K.Imai, Y.Takemoto, Y.Miura,
       H.Teshima, N.Hamajima and the Kohseisho Leukemia Study Group.
       /// Blood 83:2086-2092,1994

 12.Poor response to intensive chemotherapy in de novo acute
       myeloid leukaemia with trilineage mylodysplasia. /// K.Kuriyama,
       M.Tomonaga, T.Matsuo, T.Kobayashi, H.Miwa, S.Shirakawa,
       M.Tanimoto, K.Adachi, N.Emi, A.Hiraoka, N.Tominaga, K.Imai, N.Asou,
       K.Tsubaki, I.Takahashi, S.Minami, M.Yoshida, H.Murakami, K.Minato,
       T.Ohshima, S.Furusawa, R.Ohno and the Japan Adult Leukemia Study
       Group (JALSG). /// Br J Haematol 86:767-773,1994

 11.Japanese B cell chronic Lymphocytic leukemia:a cytogenetic and
       molecular biological study. /// H.Asou, M.Takechi, K.Tanaka,
       S.Tashiro, H.Dohy, R.Ohno and N.Kamada. /// Br J Haematol
       85:492-497,1993

 10.A randomized controlled study of granulocyte colony stimulating
       factor after intensive induction and consolidation therapy in
       patients with acute lymphoblastic leukemia. /// R.Ohno,
       M.Tomonaga, T.Ohshima, T.Masaoka, N.Asou, H.Oh, K.Nishikawa,
       A.Kanamaru, H.Murakami, S.Furusawa, M.Hirano, K.Tsubaki, K.Imai,
       T.Ueda, Y.Kuraishi, N.Ogawa, Japan Adult Leukemia Study Group
       (JALSG). /// Inter J Hematol 58:73-81,1993

   9.Treatment of acute promyelocytic leukemia with all-trans retinoic
       acid and molecular analysis of the t(15;17) translocation. ///
       T.Naoe, H.Fukutani, H.Yoshida, S.Yamamori, R.Ohno and Kouseishou
       APL Study Group. /// Cancer Chemotherapy 8:166-171,1993

   8.Randomized study of intensive individualized induction therapy with
       or without vincristine and of maintenance/intensification therapy
       in adult acute myeloid leukemia. /// R.Ohno, T.Kobayashi,
       M.Tanimoto, A.Hiraoka, K.Imai, K.Fujimoto, M.Tomonaga, K.Tsubaki,
       E.Ohmoto, Y.Kodera, H.Murakami, M.Yoshida and Japan Adult
       Leukmemia Study Group (JALSG). /// Acute
       Leukemias:645-649,1993

   7.Multi-institutional study of all-trans retinoic acid as a
       differentiation therapy of refractory acute promyelocytic leukemia.
       /// R.Ohno, H.Yoshida, H.Fukutani, T.Naoe, T.Ohshima, T.Kyo,
       N.Endoh, T.Fujimoto, T.Kobayashi, A.Hiraoka, H.Mizoguchi, Y.Kodera,
       H.Suzuki, M.Hirano, H.Akiyama, N.Aoki, H.Shindo, S.Yokomaku and
       the Leukemia Study Group of the Ministry of Health and Welfare.
       /// Leukemia 7:1722-1727,1993

    6.Randomized study of individualized induction therapy with or
       without vincristine, and of maintenance-intensification therapy
       between 4 or 12 courses in adult acute myeloid leukemia. AML-87
       study of the Japan Adult Leukemia Study Group /// R.Ohno,
       T.Kobayashi, M.Tanimoto, A.Hiraoka, K.Imai, N.Asou, M.Tomonaga,
       K.Tsubaki, I.Takahashi, Y.Kodera, M.Yoshida, H.Murakami, T.Naoe,
       M.Shimoyama, T.Tukada, T.Takeo, H.Teshima, Y.Onozawa,
       K.Fujimoto, K.Kuriyama, A.Horiuchi, I.Kimura, S.Minami, Y.Miura,
       S.Kageyama, T.Tahara, T.Masaoka, S.Shirakawa and H.Saito. ///
       Cancer 71:3888-3895,1993

   5.Current progress in the treatment of adult acute leukemia in
       Japan. /// R.Ohno. /// Japanese Journal of Clinical Oncology
       22:85-97,1993

   4.Treatment of myelodysplastic syndromes with all-trans retinoic
       acid. /// R.Ohno, T.Naoe, M.Hirano, M.Kobayashi, H.Hirai, K.Tubaki,
       H.Oh and the Leukemia Study Group of Ministry of Heath and
       Welfare. /// Blood 81:1152-1154,1993

   3.No increase of leukemia relapse in newly diagnosed patients with
       acute myeloidleukemia who received granulocyte colony-
       stimulating factor for life-threatening infection during remission
       induction and consolidation therapy. /// R.Ohno, A.Hiraoka,
       M.Tanimoto, N.Asou, K.Kuriyama, T.Kobayashi, H.Teshima, H.Saito,
       K.Fujimoto and Japan Adult Leukemia Study Group (JALSG).///
       Blood 81:561-562,1993

   2.Randomized study of individualized induction therapy with or
       without VCR, and of maintenance 4 or 12 courses in adult AML:
       JALSG-AML87 /// R.Ohno, T.Kobayashi, Y.Morishima, A.Hiraoka,
       N.Naoe and Japan Adult Leukemia Study Group (JALSG). ///
       Leukemia 6(Supplement 2):92-95,1992

   1.Effect of granulocyte colony-stimulating factor after intensive
       induction therapy in relapsed or refractory acute leukemia: ///
       R.Ohno, M.Tomonaga, T.Kobayashi, A.Kanamura, S.Shirakawa,
       T.Masaoka, M.Omine, H.Oh, T.Nomura, Y.Nakayama, Y.Yoshida,
       A.B.Miura, Y.Morishima, H.Dohy, Y.Niho, N.Hamajima and F.Takaku.
       /// N Eng J Med 323:871-877,1990